



# UNITED STATES PATENT AND TRADEMARK OFFICE

*AK*  
UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/603,283

06/25/2003

Xiao-Yu R. Song

CEN-300-NP

4429

27777

7590

02/01/2006

PHILIP S. JOHNSON  
JOHNSON & JOHNSON  
ONE JOHNSON & JOHNSON PLAZA  
NEW BRUNSWICK, NJ 08933-7003

EXAMINER

SAKELARIS, SALLY A

ART UNIT

PAPER NUMBER

1634

DATE MAILED: 02/01/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b> 10/603,283	<b>Applicant(s)</b> SONG ET AL.	
	<b>Examiner</b> Sally A. Sakelaris	<b>Art Unit</b> 1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 25 June 2003.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-35 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-35 are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

***Election/Restrictions***

1. Restriction to one of the following inventions is required under 35 U.S.C. §121:

I. Claims 1-7 and 19-21 are drawn to polynucleotides, vectors, and host cells as classified in for example Class 536, subclass 24.3.

II. Claims 8-15 are drawn to polypeptides as classified in Class 530, subclass 350.

III. Claim 17 is drawn to an antibody as classified in, Class 530 subclass 387.1

IV-VI. Claims 27-30 drawn to a method of diagnosing or treating through administration of a biomolecule such as a nucleic acid(IV), protein(V), or antibody(VI)(further restriction applies see below) as classified in for example Class 514 subclasses 44, 12, and 2.

2. Applicant is advised that examination will be restricted to only the single elected SEQ ID NO: and biomolecule(ie nucleic acid, polypeptide or Ab) and should not be construed as a species election.

Claims 16, 18, 23-26, 31-33 and 35 link the inventions of Groups I-III.

Claim 22 and 34 link the inventions of Groups I-III.

Claims 27-30 link the inventions of Groups IV-VI.

The restriction requirement between the linked inventions is subject to the nonallowance of the linking claim(s), 16, 18, 22-35. Applicant should note that since only method linking claims(22, 27-30, and 34) are present, they must elect a single biomolecule for prosecution(i.e., either the nucleic acid, protein or antibody). Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s)

Art Unit: 1634

depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

The inventions are distinct, each from the other because of the following reasons:

a. Inventions I and II are patentably distinct in structure and physiochemical properties.

Invention I is drawn to nucleic acids whereas invention II is drawn to proteins. Because nucleic acids are composed of nucleotides and proteins are composed of amino acids, the inventions have different structural and functional properties. Furthermore, the compositions are utilized in different methodologies, such that nucleic acids may be utilized in PCR amplification, while the proteins may be utilized in ligand binding assays or to generate antibodies. The protein of invention II does not require the particular products of the nucleic acids of group I since the proteins of invention II can be isolated from natural sources or chemically synthesized.

b. Inventions I and III are patentably distinct in structure and physiochemical properties.

Invention I is drawn to nucleic acids whereas invention III is drawn to antibodies. Because nucleic acids are composed of nucleotides and antibodies are composed of amino acids, the inventions have different structural and functional properties. Furthermore, the compositions are utilized in different methodologies, such that nucleic acids may be utilized in PCR amplification, while the antibodies may be utilized in assays to determine a binding partner of a protein. The nucleic acids of invention I are not required to obtain the antibodies of invention III.

Art Unit: 1634

c. Inventions II and III are patentably distinct in structure and physiochemical properties.

Invention II is drawn to polypeptides whereas invention III is drawn to antibodies. The polypeptide of Group II is composed of amino acids linked in peptide bonds and arranged spatially in a number of different tertiary structures including alpha helices, beta-pleated sheets, and hydrophobic loops (transmembrane domain). The antibody of Group III is also composed of amino acids linked in peptide bonds and arranged spatially in a very specific tertiary structure that allows that antibody to specifically bind to particular regions, i.e. epitopes, of the encoded polypeptide. Further, antibodies are glycosylated and their tertiary structure is unique, where four subunits (2 light chains and 2 heavy chains) associated via disulfide bonds into a Y-shaped symmetric dimer. The products of inventions II and III are utilized in materially different processes such that the proteins of invention II may be used to make a fusion protein while the antibodies of invention III may be used to find a binding partner of a protein. Consequently, the reagents, reaction conditions, and reaction parameters required to make or use each invention are different. Therefore, the inventions of Groups II, and III are patentably distinct from each other.

d. Inventions I and IV, II and V, and III and VI are related as products and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polynucleotides of Invention I, polypeptides of invention II and antibody of Invention III can all be used in a materially different process such as for detection molecules on an array or biochip.

Art Unit: 1634

e. Inventions I and V and VI, II and IV, VI and III, and IV and V are unrelated.

Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different functions and are not disclosed as capable of use together because polynucleotides of Invention I, polypeptides of invention II and antibody of Invention III are not required to practice the methods of inventions IV-VI involving polynucleotides, polypeptides and antibodies respectively.

f. The inventions of Groups IV- VI are patentably distinct methods because they each have different objectives, different uses, different reagents and different method steps. Group IV is drawn to a method of using a polynucleotide composition. Group V is drawn to a method of treatment using a polypeptide composition. Group VI is drawn to a method that utilizes an antibody. Since each method utilizes a different biomolecule, each method requires different method steps, objectives and reagents to accommodate the same. Therefore the methods are distinct over one another.

3. Further Restriction Requirement Applicable to All Groups:

Additionally, each group named above is subject to a further restriction. Applicant is required to further elect a single specific nucleic acid sequence from CNGH0004 and SEQ ID NO:1, OR a single CNGH0004 polypeptide from SEQ ID NO:2 or a single CNGH0004 antibody that specifically binds to a specific part of SEQ ID NO:1. This is NOT an election of species. Nucleotide sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C 121. Absent evidence to the

Art Unit: 1634

contrary, each such nucleotide sequences are presumed to represent an independent and distinct invention, subject to restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141. By statute, “[i]f two or more independent and distinct inventions are claimed in one application, the Commissioner may require the application to be restricted to one of the inventions.” 35 U.S.C. 121. Pursuant to this statute, the rules provide that “[i]f two or more independent and distinct inventions are claimed in a single application, the examiner in his action shall require the applicant...to elect that invention to which his claims shall be restricted.” 37 CFR 1.142 (a). See also 37 CFR 1.141(a).

The search and examination of all possible groups would pose an enormous burden on the examiner and on the PTO search resources. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as demonstrated by their different classification and recognized divergent subject matter due to all of the inventions’ different gene sequences would require different searches that are not coextensive, examination of these claims would pose a serious burden on the examiner and therefore the restriction is deemed proper.

It should also be noted that the method claims, if elected will be searched only for the elected molecule(DNA, protein or Ab) as referred to above in the Linking claim paragraph.. If found allowable they will be rejoined at that time.

4. Applicant is advised that the reply to this requirement, to be complete, must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Art Unit: 1634

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

6. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sally A. Sakelaris whose telephone number is 571-272-0748.

The examiner can normally be reached on M-Fri, 9-6:30 1st Friday off.




Art Unit: 1634

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones can be reached on 571-272-0745. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sally Sakelarlis

1/27/2006

  
W. Gary Jones  
Supervisory Patent Examiner  
Technology Center 1600